DK2099489T3 - Sammensætninger og fremgangsmåder til behandling af en neoplasme - Google Patents

Sammensætninger og fremgangsmåder til behandling af en neoplasme

Info

Publication number
DK2099489T3
DK2099489T3 DK07761925.2T DK07761925T DK2099489T3 DK 2099489 T3 DK2099489 T3 DK 2099489T3 DK 07761925 T DK07761925 T DK 07761925T DK 2099489 T3 DK2099489 T3 DK 2099489T3
Authority
DK
Denmark
Prior art keywords
neoplasm
procedures
compositions
treating
Prior art date
Application number
DK07761925.2T
Other languages
Danish (da)
English (en)
Inventor
Gregory D Plowman
Robert D Mass
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK2099489T3 publication Critical patent/DK2099489T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK07761925.2T 2006-12-11 2007-05-04 Sammensætninger og fremgangsmåder til behandling af en neoplasme DK2099489T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87446006P 2006-12-11 2006-12-11
PCT/US2007/068300 WO2008073509A2 (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm

Publications (1)

Publication Number Publication Date
DK2099489T3 true DK2099489T3 (da) 2014-08-18

Family

ID=38521756

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07761925.2T DK2099489T3 (da) 2006-12-11 2007-05-04 Sammensætninger og fremgangsmåder til behandling af en neoplasme

Country Status (17)

Country Link
US (1) US20100086544A1 (enExample)
EP (1) EP2099489B1 (enExample)
JP (1) JP2010512407A (enExample)
KR (1) KR101320198B1 (enExample)
CN (1) CN101547705B (enExample)
AU (1) AU2007333565A1 (enExample)
BR (1) BRPI0717688A2 (enExample)
CA (1) CA2670707A1 (enExample)
DK (1) DK2099489T3 (enExample)
IL (1) IL198852A (enExample)
MX (1) MX2009006202A (enExample)
NZ (1) NZ577058A (enExample)
RU (1) RU2482877C2 (enExample)
SG (1) SG177891A1 (enExample)
SI (1) SI2099489T1 (enExample)
WO (1) WO2008073509A2 (enExample)
ZA (1) ZA200903489B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160082T1 (hr) 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2655334B1 (en) * 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
CN104244934A (zh) * 2012-03-14 2014-12-24 印第安纳大学研究及科技有限公司 用于治疗白血病的化合物和方法
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
BR112017027798B1 (pt) 2015-07-27 2023-12-19 Chong Kun Dang Pharmaceutical Corp Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
HRP20230052T1 (hr) 2015-07-27 2023-03-03 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
NZ739211A (en) 2015-07-27 2019-05-31 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
HRP20220003T1 (hr) 2015-08-04 2022-04-01 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
FI3362445T3 (fi) 2015-10-12 2023-03-21 Chong Kun Dang Pharmaceutical Corp Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
CN113874369B (zh) 2019-05-31 2024-08-27 株式会社钟根堂 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑高邻苯二甲酰亚胺衍生化合物及包含其的药物组合物
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
CN1319090A (zh) * 1998-09-25 2001-10-24 贝林格尔英格海姆法玛公司 新的取代的二氢吲哚酮、它们的制备方法和它们作为药物的用途
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6638965B2 (en) * 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
TWI468417B (zh) * 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體

Also Published As

Publication number Publication date
BRPI0717688A2 (pt) 2013-01-22
CN101547705A (zh) 2009-09-30
SI2099489T1 (sl) 2014-09-30
CA2670707A1 (en) 2008-06-19
EP2099489A2 (en) 2009-09-16
WO2008073509A3 (en) 2009-01-08
JP2010512407A (ja) 2010-04-22
KR101320198B1 (ko) 2013-10-30
NZ577058A (en) 2012-04-27
IL198852A0 (en) 2011-08-01
US20100086544A1 (en) 2010-04-08
WO2008073509A2 (en) 2008-06-19
KR20090087908A (ko) 2009-08-18
SG177891A1 (en) 2012-02-28
ZA200903489B (en) 2010-08-25
RU2482877C2 (ru) 2013-05-27
IL198852A (en) 2013-06-27
HK1131064A1 (en) 2010-01-15
EP2099489B1 (en) 2014-05-21
MX2009006202A (es) 2009-06-22
CN101547705B (zh) 2013-06-12
AU2007333565A1 (en) 2008-06-19
RU2009126588A (ru) 2011-01-20

Similar Documents

Publication Publication Date Title
DK2041071T3 (da) Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
DK2087002T3 (da) Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
DK2032156T3 (da) Sammensætninger og fremgangsmåder til levering af oxygen
DK2323638T3 (da) Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK2203478T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antistoffer mod sclerostin
DK2066339T3 (da) Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
DK2001611T3 (da) Fremgangsmåde og sammensætning til oprensning af jord
DK2470656T3 (da) Sammensætning til hæmning af genekspression og anvendelser heraf
DK2061561T3 (da) Sammensætninger til behandling af cancer
DK1969099T3 (da) Fremgangsmåde og indretning til behandling af biomasse
DK2334932T4 (da) Anordning og fremgangsmåde til fremstilling af en anordning
DK3207941T3 (da) Fremgangsmåder og sammensætninger på basis af diphtheritoksin-interleukin-3-konjugater
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK2495327T3 (da) Fremgangsmåder og sammensætninger til at behandle og opdage sygdomme fremkaldt af fejlfoldet SOD1
ZA200903489B (en) Compositions and methods for treating a neoplasm
DK1969007T3 (da) Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
DK3006459T3 (da) Fremgangsmåde og sammensætninger til forbedring af t-cellers antitumoreffektorfunktion
DK2068927T3 (da) Fremgangsmåder til reducering af eosinofilniveauer
DK3263589T5 (da) Peptidsekvenser og sammensætninger
DK2894165T3 (da) Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
DK2133134T3 (da) Anordning og fremgangsmåde til behandling af udstødningsgas
DK2010501T3 (da) Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
DK2222999T3 (da) Fremgangsmåde til formning af en klemring og en klemring
DK2187880T3 (da) Sammensætninger og fremgangsmåder til behandling af makuladegeneration